Ligand Pharma (LGND) Pops Higher Ahead of FDA Committee Vote for Carfilzomib (ONXX)
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Join SI Premium – FREE
Ligand Pharmaceuticals (Nasdaq: LGND) shares are up 10 percent as the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is currently discussing carfilzomib's application as a treatment for multiple myeloma.
Ligand is a partner with Onyx Pharma (Nasdaq: ONXX) on the drug. The spike could be a positive indication for the outcome.
Ligand is a partner with Onyx Pharma (Nasdaq: ONXX) on the drug. The spike could be a positive indication for the outcome.
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
